PCM
PLRX icon

Prelude Capital Management’s Pliant Therapeutics PLRX Stock Holding History

Prelude Capital Management’s Portfolio PLRX Stock Details PLRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-30,782
Closed -$405K – 1452
2024
Q4 		$405K Sell
30,782
-13,618
-31% -$186K 0.03% 666
2024
Q3 		$498K Buy
44,400
+6,200
+16% +$77.6K 0.03% 632
2024
Q2 		$411K Buy
+38,200
New +$492K 0.03% 631
2024
Q1 		– Sell
-21,509
Closed -$390K – 1487
2023
Q4 		$390K Buy
+21,509
New +$327K 0.03% 627
2023
Q3 		– Sell
-13,206
Closed -$239K – 1301
2023
Q2 		$239K Buy
+13,206
New +$313K 0.02% 758

Other funds holding PLRX

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return

Prelude Capital Management's PLRX Position: Q1 2025 in Review

Prelude Capital Management sold out of Pliant Therapeutics (PLRX) in Q1 2025, closing a stake of 30,782 shares — an estimated $405K sold.

Prelude Capital Management first reported a position in PLRX in Q2 2023 and held it in 5 quarters. The position peaked at $498K in Q3 2024. 140 funds tracked by Wall St. Rank hold PLRX as of Q1 2025.

  • Prelude Capital Management reported no remaining Pliant Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Prelude Capital Management sold 30,782 Pliant Therapeutics shares in Q1 2025, an estimated $405K.
  • Prelude Capital Management first reported a position in Pliant Therapeutics in Q2 2023 and held it in 5 quarters.
  • Prelude Capital Management's Pliant Therapeutics position peaked at $498K in Q3 2024.
  • 140 funds tracked by Wall St. Rank held Pliant Therapeutics as of Q1 2025.

Based on Prelude Capital Management's 13F filing for Q1 2025, filed 15 May 2025.